Pathological outcomes in men with low risk and very low risk prostate cancer: Implications on the practice of active surveillance

Journal of Urology

Volumn 190, Issue 4, 2013, Pages 1218-1223

  Tosoian, Jeffrey J ^a   Johnbull, Eric ^a   Trock, Bruce J ^a   Landis, Patricia ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Walsh, Patrick C ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

disease progression; prostate; prostatic neoplasms; risk; treatment outcome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; TUMOR BIOPSY;

EID: 84883779475     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.04.071     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. H.G. Welch, and W.C. Black Overdiagnosis in cancer J Natl Cancer Inst 102 2010 605
3. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202
4. S. Loeb, K.A. Roehl, and B.T. Helfand Complications of open radical retropubic prostatectomy in potential candidates for active monitoring Urology 72 2008 887
5. M.R. Cooperberg, P.R. Carroll, and L. Klotz Active surveillance for prostate cancer: progress and promise J Clin Oncol 29 2011 3669
6. A. Slomski Expert panel advocates surveillance for men with low-risk prostate cancer JAMA 307 2012 133
7. H.B. Carter, P.C. Walsh, and P. Landis Expectant management of nonpalpable prostate cancer with curative intent: preliminary results J Urol 167 2002 1231
8. M.A. Dall'era, P.C. Albertsen, and C. Bangma Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976
9. J.J. Tosoian, B.J. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185
10. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228
11. M.A. Dall'Era, J.E. Cowan, and J. Simko Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment BJU Int 107 2011 1232
12. P.A. Ganz, J.M. Barry, and W. Burke National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer Ann Intern Med 156 2012 591
13. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162
14. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
15. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868
16. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
17. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725
18. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
19. L. Klotz Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes Curr Urol Rep 13 2012 153
20. J.L. Mohler The 2010 NCCN clinical practice guidelines in oncology on prostate cancer J Natl Compr Canc Netw 8 2010 145
21. S.P. Porten, J.M. Whitson, and J.E. Cowan Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance J Clin Oncol 29 2011 2795
22. R.C. van den Bergh, H. Vasarainen, and H.G. van der Poel Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study BJU Int 105 2010 956
23. S.L. Conti, M. Dall'era, and V. Fradet Pathological outcomes of candidates for active surveillance of prostate cancer J Urol 181 2009 1628
24. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
25. J. Xia, B.J. Trock, and M.R. Cooperberg Prostate cancer mortality following active surveillance versus immediate radical prostatectomy Clin Cancer Res 18 2012 5471
26. A. Adamy, D.S. Yee, and K. Matsushita Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477
27. V. Scattoni, A. Zlotta, and R. Montironi Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature Eur Urol 52 2007 1309
28. V. Iremashvili, M.S. Soloway, and D.L. Rosenberg Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance J Urol 187 2012 1594
29. J. Tosoian, and S. Loeb PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer ScientificWorldJournal 10 2010 1919
30. J.K. Mullins, M. Han, and P.M. Pierorazio Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer J Urol 187 2012 1620